GCA
AMED

Gideon Capital Advisors’s Amedisys AMED Stock Holding History

Gideon Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,658
Closed -$328K – 264
2019
Q1 		$328K Buy
2,658
+819
+45% +$103K 0.12% 257
2018
Q4 		$215K Buy
+1,839
New +$217K 0.09% 339

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Gideon Capital Advisors's AMED Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Amedisys (AMED) in Q2 2019, closing a stake of 2,658 shares — an estimated $328K sold.

Gideon Capital Advisors first reported a position in AMED in Q4 2018 and held it in 2 quarters. The position peaked at $328K in Q1 2019. 285 funds tracked by Wall St. Rank hold AMED as of Q2 2019.

  • Gideon Capital Advisors reported no remaining Amedisys position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 2,658 Amedisys shares in Q2 2019, an estimated $328K.
  • Gideon Capital Advisors first reported a position in Amedisys in Q4 2018 and held it in 2 quarters.
  • Gideon Capital Advisors's Amedisys position peaked at $328K in Q1 2019.
  • 285 funds tracked by Wall St. Rank held Amedisys as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.